Faculty profile
Clarence Geyer
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Saskatchewan directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $875,925
Ultrasound molecular imaging of intestinal stenosis: Developing a contrast agent to distinguish between inflammatory and fibrotic strictures in patients with inflammatory bowel disease
CIHR · 2024 · Co-investigator
- $719,100
A theranostic probe targeting the tumor-associated xenoantigen N-Glycoylneuramic acid GM3 ganglioside (Neu5Gc GM3)
CIHR · 2024 · Nominated PI
- $963,900
Tumor targeted, radiolabeled, mimetic nanovesicle theranostics for imaging and treating head and neck cancer
CIHR · 2023 · Principal investigator
Ultrasound molecular imaging of intestinal stenosis: Developing a contrast agent to distinguish between inflammatory and fibrotic strictures in patients with inflammatory bowel disease
Principal investigators: Machtaler, Steven B
Keywords: Aptamers; Bowel Strictures; Inflammation; Inflammatory Bowel Disease; Microbubbles; Ultrasound Molecular Imaging
A theranostic probe targeting the tumor-associated xenoantigen N-Glycoylneuramic acid GM3 ganglioside (Neu5Gc GM3)
Principal investigators: Geyer, Clarence R; Price, Eric W
Keywords: 177-Lutetium; 90-Yttrium; H14f7 Antibody; Neu5gc Gm3; Radio-Immunotherapy; Solid Tumors; Spect-Ct; Theranostic; Xeno-Antigen
Tumor targeted, radiolabeled, mimetic nanovesicle theranostics for imaging and treating head and neck cancer
Principal investigators: Price, Eric W; Geyer, Clarence R
Keywords: Bioconjugation Chemistry; Head And Neck Cancer; Mimetic Nanovesicle; Nanoparticles; Positron Emission Tomography; Radioimmunotherapy; Radionuclide Therapy; Targeted Radionuclide Therapy; Theranostics; Zirconium-89
Simultaneous targeting of multiple domains of HER2 and EGFR using domain-specific alpha particle labeled radioimmunoconjugates
Principal investigators: Fonge, Humphrey A
Keywords: Alpha Particle Radiotherapy; Antibody Drug Conjugates; Breast Cancers; Egfr; Her2; Micropet Imaging; Mouse Models; Nuclear Medicine; Personalized Medicine; Radioimmunotherapy
Design of synthetic recombinant antibody devices for applications in molecular targeted imaging
Principal investigators: Geyer, Clarence
Alpha particle-labeled antibody-drug radioconjugates for radiotherapy of metastatic colorectal cancer (mCRC)
Principal investigators: Fonge, Humphrey A
Keywords: Actinium-225; Alpha Particle Radiotherapy; Epidermal Growth Factor Receptor; Metastic Colorectal Cancer; Patient Derived Xenografts; Precision Medicine; Radiation Dosimetry; Radioimmunotherapy; Radiopharmaceuticals; Spect/Pet Imaging
Systematic profiling of circular RNAs essential for the survival of cancer cells
Principal investigators: Vizeacoumar, Franco J; Geyer, Clarence R
Keywords: Circularrnas; Non-Coding Rnas
Antibodies Targeting the ErbB2/ErbB3/IGF-1R Complex as Therapeutics for ErbB2 Positive Breast Cancer
Principal investigators: Liu, Jianghai
Keywords: Antibody Therapy For Breast Cancer; Erbb Receptors; Igf-1 Receptor; Phage Display
The Role of Insulin-like Growth Factor-1 (IGF-1) Signaling on Chronic Phase and Blast Crisis Phase of Chronic Myeloid Leukemia
Principal investigators: Abrishami, Mahsa
Keywords: Chronic Myeloid Leukemia Stem Cells; Cytokines; Innate Imatinib Resistance Mechanisms; Insulin-Like Growth Factor And Drug Resistance In Leukemia
The Role of Natural Antisense Transcripts in Silencing Transforming Growth Factor Beta Regulated Genes in Acute Myeloid Leukemia
Principal investigators: Geyer, Clarence R
Keywords: Acute Leukemia; Cyclin-Dependent Kinase Inhibitors; Dna Methylation; Epigenetics; Histone H3k9 Methylation; Histone Modifications; Natural Antisense Transcripts; Transforming Growth Factor Beta
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.